0001253689 false 0001253689 2024-06-04 2024-06-04

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): June 4, 2024

​

​

GlycoMimetics, Inc.

(Exact name of registrant as specified in its charter)

​

​ | ​ | ​ | ​ | ​
Delaware | ​ | 001-36177 | ​ | 06-1686563
(State or other jurisdiction of incorporation) | ​ | (Commission File Number) | ​ | (IRS Employer Identification No.)

​

9708 Medical Center Drive

Rockville, MD 20850

(Address of principal executive offices, including zip code)

​

(240) 243-1201

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.001 par value | GLYC | The Nasdaq Stock Market

​

Indícate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​ | ​ | ​
​ | ​ | ​

​

​

​

Item 7.01.Regulation FD Disclosure.

​

On June 4, 2024, GlycoMimetics, Inc. (the “Company”) issued a press release announcing comprehensive results from its pivotal Phase 3 clinical trial of uproleselan in patients with relapsed/refractory acute myeloid leukemia. On June 4, 2024, the Company also hosted a live webcast to discuss the results. The press release and slide presentation used during the webcast are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report and are incorporated herein solely for purposes of this Item 7.01 disclosure.

​

The information in this Item 7.01, including the exhibits attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such filing, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

9, |  |
Exhibit |  |
Number |  | Exhibit Description
99.1 |  | Press release, dated June 4, 2024, “GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML).”
99.2 | ​ | Corporate Presentation, June 4, 2024.
104 |  | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

​

​

​

​

​

​

2

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

| ​ | ​
​ | ​ | GLYCOMIMETICS, INC.
​ | ​ | ​
​ | By: | /s/ Brian M. Hahn
Date: June 4, 2024 | ​ | Brian M. Hahn Senior Vice President and Chief Financial Officer

​

​

​

3